Tim Alcorn, Ph.D., Managing Director, Medical Devices, Diagnostics, and Health IT, was recently asked to contribute to a paper titled “Smart Diagnostics: Combining Artificial Intelligence and In Vitro Diagnostics,” which was published in Sensors by MDPI.
The paper focuses on specific uses for Smart Diagnostics, including COVID-19, cardiovascular disease, and oral cancer, which serve as good examples of how Smart Diagnostics can be applied to many diseases and conditions for point-of-care disease management.
“These example applications provide good templates for how companies should clinically validate Smart Diagnostics and how diagnostics outputs should be presented for best clinical utilization,” says Dr. Alcorn.
One of four authors, Dr. Alcorn provided input on the clinical and commercial implementation and use of Smart Diagnostics as well as input on regulatory considerations.
An experienced clinical chemist and molecular biologist with more than 25 years of experience in the healthcare industry, Dr. Alcorn began his career at the University of North Carolina, where he focused on sexually transmitted diseases pathobiology and vaccine development. However, he has worked in a variety of healthcare sectors throughout his career, including reference laboratories, medical device manufacturing, medical software development, in vitro device development, and pharmaceutical development.
Dr. Alcorn has extensive experience in infectious diseases and served as the laboratory director at LabCorp’s Center for Molecular Biology and Pathology, where he developed advanced clinical assays and managed a laboratory that generated more than $50 million in revenue. In addition, he was Director of Clinical Affairs at Janssen Diagnostics, Inc. and helped bring new diagnostics and software to the global market to support the launch of drugs for the treatment of HIV and HCV.
In addition to this paper, LBG has also been collaborating with NYU on several projects related to Smart Diagnostics or diagnostics that incorporate Artificial Intelligence or similar data-driven engines to improve accuracy and clinical utilization. They previously collaborated on an AI tool for the prediction of COVID-19 severity.
To view the paper, click here! *
To learn more, visit mdpi.com
